Business & Finance
Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
Key Points
Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess. The US regulator made observations in a complete response letter following a pre-license inspection and Galderma is putting in place corrective and preventive actions, the company said in a statement Wednesday. The stock fell as much as 6.6%,...
Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.
The US regulator made observations in a complete response letter following a pre-license inspection and Galderma is putting in place corrective and preventive actions, the company said in a statement Wednesday. The stock fell as much as 6.6%, the most intraday since April 2025.